ASH: Bristol's 3rd-line Abecma data didn't make the trip to New Orleans. Is it cause for concern?

As companies eagerly trumpet new data for their BCMA-targeted therapies at the ASH 2022 annual meeting, Bristol Myers Squibb’s much-anticipated third-line multiple myeloma data for Abecma were mysteriously missing.